The Current Ratio as of November 2024 (TTM) for Ultragenyx Pharmaceutical Inc. (RARE) is 2.81

According to Ultragenyx Pharmaceutical Inc.’s latest financial reports and current stock price. The company's current Current Ratio is 2.81. This represents a change of -1.37% compared to the average of 2.84 of the last 4 quarters.

Ultragenyx Pharmaceutical Inc. (RARE) Historical Current Ratio (quarterly & annually)

How has RARE Current Ratio performed in the past?

The mean historical Current Ratio of Ultragenyx Pharmaceutical Inc. over the last ten years is 7.56. The current 2.81 Current Ratio has changed 3.61% with respect to the historical average. Over the past ten years (40 quarters), RARE's Current Ratio was at its highest in in the March 2015 quarter at 24.61. The Current Ratio was at its lowest in in the September 2023 quarter at 2.06.

Ultragenyx Pharmaceutical Inc. (RARE) Current Ratio by Quarter and Year

Discovering the peaks and valleys of Ultragenyx Pharmaceutical Inc. Current Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

Ultragenyx Pharmaceutical Inc. (RARE) Average Current Ratio

How has RARE Current Ratio performed in the past?

The current Current Ratio of Ultragenyx Pharmaceutical Inc. (RARE) is less than than its 3-year, less than than its 5-year, and less than than its 10-year historical averages

Ultragenyx Pharmaceutical Inc. (RARE) Current Ratio vs. Peers

How is RARE’s Current Ratio compared to its peers?

Ultragenyx Pharmaceutical Inc.’s Current Ratio is less than X4 Pharmaceuticals, Inc. (4.89), less than Terns Pharmaceuticals, Inc. (32.99), less than Day One Biopharmaceuticals, Inc. (14.62), greater than PDS Biotechnology Corporation (0.00), less than Inozyme Pharma, Inc. (7.68), less than Mirati Therapeutics, Inc. (7.54), less than Amylyx Pharmaceuticals, Inc. (4.55), less than Apellis Pharmaceuticals, Inc. (4.36), less than Crinetics Pharmaceuticals, Inc. (16.38), less than Arvinas, Inc. (4.17), less than Revolution Medicines, Inc. (14.24), less than Kura Oncology, Inc. (11.47), less than Acumen Pharmaceuticals, Inc. (10.43), greater than Incyte Corporation (1.87), greater than Alnylam Pharmaceuticals, Inc. (2.75), less than United Therapeutics Corporation (4.58),

Build a custom stock screener for Ultragenyx Pharmaceutical Inc. (RARE) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Ultragenyx Pharmaceutical Inc. using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

Ultragenyx Pharmaceutical Inc. (RARE) and other stocks custom spreadsheet templates

The easiest way to analyze a company like Ultragenyx Pharmaceutical Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.